Search results
Results From The WOW.Com Content Network
Dofetilide is used for the maintenance of sinus rhythm in individuals prone to the occurrence of atrial fibrillation and flutter arrhythmias, and for chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. [5] [6]
Bictegravir should not be used with dofetilide and rifampin. [16] Use of dofetilide with bictegravir increases the concentration of dofetilide, which can lead to life-threatening events. [16] Concomitant use of bictegravir and rifampin causes significant interactions because of an effect rifampin has on bictegravir. [16]
Reverse use dependence is the effect where the efficacy of the drug is reduced after repeated use of the tissue. [11] This contrasts with (ordinary) use dependence, where the efficacy of the drug is increased after repeated use of the tissue. Reverse use dependence is relevant for potassium channel blockers used as class III antiarrhythmics.
Ozempic has taken the world by storm – largely due to the medication's weight loss effect and rumored use by celebrities and the wealthy.. But some physicians want to shift this narrative ...
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells.
A pal at the Brooklyn facility where he last shacked up told The Post the migrant was addicted to smoking the synthetic drug K2 and drank heavily on a daily basis.. The accused killer allegedly ...
While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use. [2] Use remains recommended after the first trimester. [2] It should not be used with dofetilide. [3]
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.. The ...